Iron Overload in NTDT 3rd Pan-European Conference on Haemoglobinopathies & Rare Anaemias Limassol, 24 – 26 October 2012 Khaled M. Musallam, MD, PhD American.

Slides:



Advertisements
Similar presentations
Iron Overload in Chronic Anaemias Dick Wells MD, DPhil, FRCPC Director, Crashley Myelodysplastic Syndrome Research Laboratory Odette Cancer Centre.
Advertisements

Update on Imaging: Detection of Iron in Liver and Heart Tim St. Pierre, BSc, PhD Professor School of Physics The University of Western Australia Crawley,
1 Rash and Low T2* MRI in a Paediatric Thalassaemia Patient.
Clinical Case: Managing Iron Overload in a Patient with Transfusion- Independent Thalassaemia Intermedia Ali T. Taher, MD Professor Department of Internal.
Faculty of Applied Medical Sciences Department Of Medical Lab. Technology 2 nd Year – Level 4 – AY Mr. Waggas Ela’as, M.Sc, MLT.
Mediterranean Anemia-Thalassemia
Non-Transfusion-Dependent Thalassemia
1 Indications for Successful Iron Overload Treatment and Monitoring: Sickle Cell Disease Mariane de Montalembert, MD Pediatrics Department University Hospital.
Slide 1 of 16 Dose Titration in a Patient with Myelodysplastic Syndromes.
Pathophysiology of cardiovascular disease in haemoglobinopathies and rare anaemias 3rd Pan European Conference on haemoglobinopathies and rare anaemias.
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
Osteoporosis in Thalassemia: Pathogenesis and Treatment Update Pat Mahachoklertwattana M.D. Department of Pediatrics, Ramathibodi Hospital Faculty of Medicine,
Ingested mg/day Ingested mg/day Absorbed 1-2 mg/day Absorbed 1-2 mg/day Lost Gut, skin, urine mg/day Menses - 30 mg/month Lost Gut,
Clinical Trial Results. org Tilman B. Drüeke, M.D.; Francesco Locatelli, M.D.; Naomi Clyne, M.D.; Kai-Uwe Eckardt, M.D.; Iain C. Macdougall, M.D.; Dimitrios.
IRON 7 mg/1000 cal in diet; 10% absorbed Heme iron absorbed best, Fe 2+ much better than Fe 3+ –Some foods, drugs enhance and some inhibit absorption of.
Hypercoagulability and Thrombosis
HEREDITARY HAEMOCHROMATOSIS. What Is It? An inherited disease characterised by excess iron deposition in various organs Leads to eventual fibrosis and.
HEMOCHROMATOSIS Wendy Graham, MD, CCFP Academic ½ Day November 25, 2003.
QUANTITATIVE IMAGING OF HUMAN LIVER IRON CONCENTRATIONS IN VIVO
Managing Iron Overload in Beta Thalassemia Major: Focus on Cardiac Iron Ali Taher, MD American University of Beirut Lebanon.
Diagnosis of Iron Overload
iron overload in haemoglobinopathies
Iron: Can’t live without enough of it Can’t live with too much of it
End-organ damage resulting from accumulation of iron in cells Pierre Brissot University Hospital Pontchaillou, Rennes, France.
Ali Taher, MD, FRCP Professor Department of Internal Medicine
Metabolic Factors / NAFLD on the Natural History of Chronic Hepatitis B or C in Asia Pei-Jer Chen National Taiwan University & Hospital.
 Ali Taher,1 Chaim Hershko2 and Maria Domenica Cappellini.
Investigating haemoglobinopathies. Carrier frequencies of thalassaemia alleles (%) Regionβ-Thalassaemiaα 0 -Thalassaemiaα + -Thalassaemia Americas 0–30–50–40.
Noncompliance with Iron Chelation Therapy in an Adolescent with Thalassaemia Major Adlette C. Inati, MD Head, Division of Pediatric Hematology-Oncology.
EHA & WFH HIGHLIGHTS July 30-31, 2010 Rest House Tyr Lebanon.
Efficacy and Safety of Deferasirox (Exjade®) during 1 Year of Treatment in Transfusion-Dependent Patients with Myelodysplastic Syndromes: Results from.
● Assoc Prof Antonis Kattamis Division of Hematology-Oncology, Head First Department of Pediatrics, University of Athens, Greece.
Thalassemia Workshop: Chelation Therapy Chi-Kong Li, MBBS, MD Department of Paediatrics Prince of Wales Hospital The Chinese University of Hong Kong BTG.
ACTIVE Clopidogrel plus Aspirin versus Aspirin in Patients Unsuitable for Warfarin.
Cognitive Impairment: An Independent Predictor of Excess Mortality SACHS, CARTER, HOLTZ, ET AL. ANN INTERN MED, SEP, 2011;155: ZACHARY LAPAQUETTE.
Epidemiology and Disease Pathophysiology: Thalassaemia
Transferrin therapy ameliorates disease in β-thalassemic mice Alisha Juman Lakeland High School Grade 10 Li H, Rybicki AC, Suzuka SM, et al. Nat Med
Approaches to management of β-thalassemia intermedia Ali Taher, MD, PhD, FRCP American University of Beirut Medical Center.
Clinical Considerations for Managing Iron Overload in MDS: Analysis From EHA Aristoteles Giagounidis, MD, PhD Associate Professor of Medicine Head, Hematology/Oncology.
CU-1 Iron Overload: Complications and Need for Therapy John B. Porter, MD Professor of Hematology University College, London, UK.
Multicenter Study of Down-staging of Hepatocellular Carcinoma (HCC) to within Milan Criteria before Liver Transplantation Neil Mehta, MD; Jennifer Guy,
Review of literature and report of experience with erythropoietin in ESRD populations Summary to FDA Cardio Renal Committee J. Michael Lazarus, M.D. CMO.
THROMBOTIC COMPLICATIONS IN PATIENTS WITH POLYCYTHEMIA VERA Coordinator: Asist. Univ. Dr. Marcela Candea Authors: Ioana-Violeta Oltean Ioana Barsan Madalina.
Cardiac Effects of Iron Overload
TRACE ELEMENTS IRON. IRON METABOLISM DISTRIBUTION OF IRON IN THE BODY Between 50 to 70 mmol (3 to 4 g) of iron are distributed between body compartments.
Metabolism of iron Alice Skoumalová. Iron in an organism:  total 3-4 g (2,5 g in hemoglobin)  heme, ferritin, transferrin  two oxidation states: Fe.
Duration of Anticoagulation 5 Patients Categories 3. First Episode: 4. First Episode: 5.Recurrent DVT 2. First Episode: 1. First Episode: Transient risk.
M. Domenica Cappellini, MD
IRON METABOLISM IRON DEFICIENCY IRON OVERLOAD
Thalassemia Center 1 Iron Overload in Chronic Anaemias.
Vitamin D deficiency and anemia in early chronic kidney disease 2010/05/18 R4 이완수 2010.
Peripheral Artery Disease in Orthopaedic Patients with Asymptomatic Popliteal Artery Calcification on Plain X-ray Adam Podet, MS; Julia Volaufova, phD,;
Points to be discussed:  Definitions  Patho-physiology  Signs & Symptoms  Diagnosis  Options of management.  Complications  Preventive measures.
AHMED KADHIM THALASSEMIA CENTER - DUBAI. Background Iron chelating agents (desferroxamine and deferazirox) are mainly used to prevent the deleterious.
Presented by : Fawziya Alyafei ped endocrine fellow ped endocrine fellow Department of Pediatrics Endocrinology and Hematology Hamad Medical Center, Qatar.
ANCO 2006 ASH UPDATE MDS Joseph M. Tuscano, M.D. UC Davis Cancer Center.
Interactions Between COPD and Outcomes After Percutaneous Coronary Intervention Tomas Konecny, Krishen Somers, Marek Orban, Yuki Koshino, Ryan J. Lennon,
Anemia in CKD The TREAT Trial Reference Pfeiffer MA. A trial of Darbepoetin alpha in type II diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.
 Disorders of iron metabolism are evaluated primarily by : 1. packed cell volume 2. Hemoglobin & red cell count and indices 3. Total iron and TIBC, percent.
Heart & Thalassemia . R.Miri,MD, Interventional Cardiologist.
在使用Sorafenib治療肝細胞癌過程中患有
Yasuj 1394.
Surgical ICU, Heart Institute University of São Paulo
by Khaled M. Musallam, Vijay G
MYELODYSPLASTIC SYNDROME: prognosis & treatment options
If platelets are not a prognostic factor
Clinical Case: Managing Iron Overload in a Patient with Transfusion-Independent Thalassaemia Intermedia Ali T. Taher, MD Professor Department of Internal.
Molecular Pathophysiology of Iron Disorders
Niels Grote Beverborg et al. JCHF 2018;6:
Iron overload in Sickle Cell disease
Presentation transcript:

Iron Overload in NTDT 3rd Pan-European Conference on Haemoglobinopathies & Rare Anaemias Limassol, 24 – 26 October 2012 Khaled M. Musallam, MD, PhD American University of Beirut, Beirut, Lebanon University of Milan, Milan, Italy

● Primary: Increased intestinal absorption ● Secondary: Blood transfusions Excess Iron in NTDT Musallam KM et al. Blood Rev 2012;26:16-9.

● Occasional Infection Pregnancy Surgery ● More regular Poor growth and development Specific complications (advanced age)  Leg ulcer, pulmonary hypertension, extramedullary hematopoietic psuedotumors, thrombotic disease Transfusions in NTDT Musallam KM et al. Cold Spring Harb Perspect Med 2012;2:a

Primary Iron Overload Musallam KM et al. Blood Rev 2012;26:16-9. Ginzburg Y and Rivella S. Blood 2011;118: Ineffective erythropoiesis, Anemia, Hypoxia ↓ Hepcidin↑ Erythropoietin ↓ Ferroportin ↑ Intestinal absorption ↑ Release of recycled iron from reticuloendothelial system ↑ Liver iron concentration ↓ Than expected serum ferritin level GDF-15 TWGF-1 HIFs Tmprss6 ? Other erythroid regulators

Primary Iron Overload (2) r=0.63, P= r=0.36, P= Musallam KM et al. Blood Cells Mol Dis 2011;47: Taher AT et al. Br J Haematol 2009;146:

● Cumulative process Positive correlations between iron overload indices and advancing age 1-5 ● Slower than transfusional siderosis 3-4 mg/day or as much as 1,000 mg/year 6 Annual increase in liver iron concentration of 0.38 ± 0.49 mg Fe/g dry 7 Iron Overload in NTDT 1.Taher A et al. Br J Haematol 2009;146: Taher AT et al. Br J Haematol 2010;150: Taher A et al. Haematologica 2008;93: Lal A et al. N Engl J Med 2011;364: Chen FE et al. N Eng J Med 2000;343: Musallam KM et al. Blood Rev 2012;26: Taher AT et al. Blood 2012;120: β-thalassemia intermedia 2 Hemoglobin H disease 5 r=0.65 P<0.001

Considerable iron overload warranting concern? ● Iron overload as early as 5 years 1 ● Iron-related morbidities beyond 10 years 2 ● Mean LIC values at cross-sectional assessment of NTDT cohorts with a mean age in early-mid adulthood range between 7 and 15 mg Fe/g dw Cossu P et al. Eur J Pediatr 1981;137: Taher AT et al. Br J Haematol 2010;150: Origa R et al. Haematologica 2007;92: Musallam KM et al. Haematologica 2011;96: Taher AT et al. Blood 2012;120: Lal A et al. N Engl J Med 2011;364: Pakbaz Z et al. Pediatr Blood Cancer 2007;49:

The Heart Serum ferritin (ng/mL) Cardiac T2* (ms) Normal LIC (< 3 mg Fe/g dry wt) Mild LIC (3–7 mg Fe/g dry wt) Moderate LIC (7–15 mg Fe/g dry wt) Severe LIC (> 15 mg Fe/g dry wt) Normal cardiac R2* LIC (mg Fe/g dry wt) Cardiac R2* (Hz) 1.Origa R et al. Haematologica 2008;93: Roghi A et al. Ann Hematol 2010;89: Taher AT et al. Am J Hematol 2010;85: Mavrogeni S et al. Int J Cardiovasc Imaging 2008;24: n=20 n=49 No evidence of cardiac siderosis even in NTDT patients with considerable iron overload 1-4

The Liver ● Several case reports and case series suggest an association between iron overload and hepatocellular carcinoma in hepatitis C negative patients with NTDT Macaron J et al. Ann Hepatol In Press. 2.Restivo Pantalone G et al. Br J Haematol 2010;150: Borgna-Pignatti C et al. Br J Haematol 2004;124: Mancuso A. World J Hepatol 2010;2:171-4.

The Liver (2) Musallam KM et al. Blood Cells Mol Dis 2012;49: Chelated Non-chelated ● β-TI (n=42) ● Median age 38 yrs, 50% men ● Hepatitis C negative ● 28 non-chelated, 14 chelated ● Two consecutive Transient Elastography (FibroScan®) measurements (median 2 yrs, range 1-3 yrs) R 2 : P<0.001

The Liver (3) Musallam KM et al. Blood Cells Mol Dis 2012;49: ● ∆ TE in non-chelated patients: 4.4 to 5.7 kPa, P<0.001 ● ∆ TE in chelated patients: 7.0 to 4.7 kPa, P=0.005 ● ∆ TE/yr non-chelated vs. chelated: +0.3 vs kPa/year, P<0.001 S <3 (n=11) S 3 (n=1) S 4 (n=1) S 5 (n=1) S <3 (n=11) S 3 (n=3) S <3 (n=28)S <3 (n=26) S 3 (n=2) First measurement Last measurement Chelated Non-chelated Transient elastography values corresponding to fibrosis stages are: ≤7.9 kPa for S 7.9 to 10.3 for S 3; >10.3 to 12.0 for S 4; and >12.0 for S 5.

Other Morbidities Musallam KM et al. Haematologica 2011;96: Morbidity absent Morbidity present LIC (mg Fe/g dry wt) Leg ulcers p = EMH Heart failure Diabetes mellitus p = 0.490p = 0.245p = Thrombosis PHT ALF Hypothyroidism Osteoporosis Hypogonadism p = p < p = 0.040p < non-chelated β-TI, mean age 35.2 yrs, mean LIC 8.4 mg Fe/g dw On multivariate analysis, a 1 mg Fe/g dw increase in LIC was significantly associated with higher odds of thrombosis, pulmonary hypertension, hypothyroidism, osteoporosis, and hypogonadism Adjusted for age, gender, splenectomy status, transfusion history, total hemoglobin level, fetal hemoglobin level, platelet count, NRBC count, and serum ferritin level On multivariate analysis, a 1 mg Fe/g dw increase in LIC was significantly associated with higher odds of thrombosis, pulmonary hypertension, hypothyroidism, osteoporosis, and hypogonadism Adjusted for age, gender, splenectomy status, transfusion history, total hemoglobin level, fetal hemoglobin level, platelet count, NRBC count, and serum ferritin level

Other Morbidities (2) Musallam KM et al. Haematologica 2011;96: Morbidity LIC cut-off (mg Fe/g dry wt) AUC95% CI p valueSensitivitySpecificityAOR (95% CI) a Thrombosis≥ ± – %61.3%2.86 (1.22–5.91) Pulmonary hypertension ≥ ± –0.767< %58%3.30 (1.54–7.08) Vascular b ≥ ± –0.800< %71.8%3.76 (1.81–7.81) Hypothyroidism≥ ± – %52.2%2.65 (1.03–6.77) Osteoporosis≥ ± –0.787< %81.3%5.13 (2.46–10.71) Hypogonadism≥ ± – %52.1%3.35 (1.2–9.26) Endocrine c ≥ ± –0.801< %70.3%4.05 (1.96–8.35) a Adjusted for age, gender, splenectomy status, transfusion history, total hemoglobin level, fetal hemoglobin level, platelet count, NRBC count, and serum ferritin level. Model was built using forward-stepwise selection. p ≤ 0.1 was used as the criterion for inclusion. Multi-colinearity was absent in the model as evident from a variation inflation factor ≤ 3 (acceptable limit up to 10). b Patients having PHT or thrombosis. c Patients having hypothyroidism, osteoporosis, or hypogonadism.

Other Morbidities (3) Musallam KM et al. Eur J Haematol 2011;87: >0.8 <0.7 <0.5 <0.3 <0.1 Probability Probability of Stenosis on MRA Total Hemoglobin (g/l) NTBI (µmol/l) ● 29 β-TI ● Splenectomized ● Mean age 32 yrs ● Significant association between the occurrence of large-vessel cerebrovascular disease (MRA) and high NTBI levels

Other Morbidities (4) Musallam KM et al. Ann Hematol 2012;91: ● 30 β-TI ● Splenectomized ● Mean age 32 yrs ● Significant association between decreased neuronal function (PET-CT) and high LIC 1.0 LIC (mg Fe/g dry wt) II IIII I I I I I I I I I Probability of abnormality on PET-CT 0

Association with vascular disease truly causal? Splenectomy n (%) Transfusion n (%) LIC (mg Fe/g dw) n (%) Vascular morbidity n (%) + P<0.001 P=0.016 P=0.001 N=168 No 47 (28) Yes 121 (72) Yes 103 (85.1) No 18 (14.9) Yes 21 (44.7) No 26 (55.3) <7 23 (88.5) ≥7 3 (11.5) <7 27 (69.2) ≥7 12 (30.8) <7 39 (37.9) ≥7 64 (62.1) 47 (73.4) 16 (41) 7 (58.3) 9 (33.3) 1 (33) 3 (13) P=0.020 P<0.001 Mild phenotype (neither splenectomized nor transfused) Moderate phenotype (either splenectomized or transfused) Severe phenotype (both splenectomized and transfused) Musallam KM et al. Haematologica 2011;96:

*p < 0.05; **p < 0.01; ***p < Probability of vascular morbidity Age (years) LIC < 7 mg Fe/g dry wt LIC ≥ 7 mg Fe/g dry wt * ** Mild phenotype (neither splenectomized nor transfused) Moderate phenotype (either splenectomized or transfused) Severe phenotype (both splenectomized and transfused) Probability of vascular morbidity Age (years) LIC < 7 mg Fe/g dry wt LIC ≥ 7 mg Fe/g dry wt ** Association with vascular disease truly causal? (2) Musallam KM et al. Haematologica 2011;96:

Musallam KM et al. Thromb Res 2012;130:

Assessment of Iron Overload ● Serum ferritin ● Liver iron concentration ● SQUID ● MRI ● Biopsy ● Cardiac MRI? ● Other markers (NTBI, Transferrin Sat)? Musallam KM et al. Blood Rev 2012;26:16-9.

Spot Serum Ferritin Measurement ● Caution with interpreting spot serum ferritin values to tailor iron chelation therapy in NTDT ● The 1000 and 2500 ng/ml thresholds are used in thalassemia major patients as they predict survival and cardiac outcomes -> less relevant in NTDT and no similar predictive assessment exists ● Although serum ferritin correlates with LIC in NTDT 1-4, the ratio of serum ferritin to LIC is lower relative to patients with β-thalassemia major 1,4-6 1.Taher A et al. Haematologica 2008;93: Lal A et al. N Engl J Med 2011;364: Taher AT et al. Blood 2012;120: Pakbaz et al. Pediatr Blood Cancer 2007;49: Origa R et al. Haematologica 2007;92: Taher AT et al. Am J Hematol 2010;85:

Serum Ferritin vs. LIC in TI and TM 1,000 2,000 3,000 4,000 5,000 6,000 7,000 8,000 9,000 10, LIC (mg Fe/g dry wt) Serum ferritin level (μg/L) TITM Linear (TI) Linear (TM) 0 Taher A et al. Haematologica 2008;93:

Conclusions ● NTDT patients show considerable iron overload despite their transfusion-independence ● Ineffective erythropoiesis leading to hepcidin suppression and increased intestinal iron absorption is the primary implicated mechanism ● Iron overload in this patient population is associated with morbidities involving several organs and organ systems ● Timely detection is warranted, and caution regarding serum ferritin level interpretation is essential